Quote:
Originally Posted by 1andrew1
I guess contract manufacturers are making the vaccine at no/minimal profit but gain in the long run on experience and technology transfer from AstraZeneca?
|
That's an interesting point. If the contract manufacturers are making COVID vaccines, they won't be making other products for other customers so I had a quick look at Oxford Biomedica and this was in their
interim report for 2020;
Quote:
In September, the Group announced an 18-month supply agreement under a three-year Master Supply and
Development Agreement with AstraZeneca for large-scale manufacture of AZD1222, for which the Group was
paid a £15 million capacity reservation fee. The Group expects, subject to satisfactory scale up of the process
and continuation of the vaccine programme, to receive additional revenues in excess of £35 million until the
end of 2021
|
That seems to be about half their annual revenue but certainly not all of their production capacity